Form 4: Astria Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Andrew Komjathy, Chief Commercial Officer of Astria Therapeutics, received stock options for 225,000 shares on March 21, 2025.
Summary
- Andrew Komjathy, the Chief Commercial Officer of Astria Therapeutics, Inc. (ATXS), was granted stock options on March 21, 2025.
- The options are for 225,000 shares of Astria Therapeutics common stock.
- The exercise price of the options is $6.41 per share.
- The options vest over a four-year period, starting with 25% vesting on February 13, 2026, and the remainder vesting in equal monthly installments over the following three years.
- The options expire on March 20, 2035.
Sentiment
Score: 7
Explanation: The granting of stock options is generally viewed positively as it aligns management's interests with shareholders. It suggests confidence in the company's future prospects.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.
Future Outlook
The vesting schedule suggests a long-term commitment from the executive to the company's success.
Industry Context
Granting stock options is a common practice in the biotechnology industry to attract and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
- Companies like BioMarin, Vertex, and Sarepta Therapeutics also utilize stock options as part of their executive compensation strategy.
- The vesting schedule and exercise price are typically determined based on factors such as market conditions, company performance, and individual contributions.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Base date for vesting schedule. |
| 03/21/2025 | Date of stock option grant. |
| 03/25/2025 | Date of Form 4 filing. |
| 02/13/2026 | First vesting date (25% of shares). |
| 03/20/2035 | Expiration date of the stock options. |
Keywords
stock options, Astria Therapeutics, executive compensation, Form 4, ATXS, Komjathy, Chief Commercial Officer, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.